Novo Nordisk A/S (NYSE:NVO) Trading Down 0.4%

Novo Nordisk A/S (NYSE:NVO) fell 0.4% during trading on Wednesday . The company traded as low as $121.79 and last traded at $123.45. 3,044,113 shares were traded during mid-day trading, a decline of 15% from the average session volume of 3,581,832 shares. The stock had previously closed at $123.90.

Analyst Ratings Changes

A number of brokerages recently commented on NVO. BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. UBS Group began coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday, April 1st. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Trading Down 0.4 %

The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company has a 50-day simple moving average of $126.16 and a 200 day simple moving average of $110.32. The firm has a market cap of $553.99 billion, a PE ratio of 45.72, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.33 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is presently 48.89%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Cornerstone Planning Group LLC acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at $29,000. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter worth $25,000. Tower Research Capital LLC TRC grew its holdings in shares of Novo Nordisk A/S by 165.3% during the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock worth $32,000 after purchasing an additional 124 shares during the period. CNB Bank purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $26,000. Finally, Pacific Center for Financial Services grew its holdings in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.